Thromboembolic complications of SARS-CoV-2: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Adelaide Iervolino.

Covid-19 has the potential to cause severe damage to many tissues, including systemic inflammatory response syndrome (SIRS), acute respiratory disease syndrome (ARDS), multiorgan involvement, and shock. One of the most feared complications are thromboembolic events which lead to severe clinical phenotypes: worsening of pulmonary conditions, oxygen desaturation, and acute respiratory distress. Management choices should be considered according to the critical or chronic setting.                             Main pathophysiological mechanisms underlying thrombosis from Covid-19 are discussed, including metabolic derangements and hormonal factors.

  • thromboembolism
  • COVID-19 infection
  • pathophysiology
  • obesity
  • insulin
  • metabolism
Please wait, diff process is still running!

References

  1. Xie, Y.; Wang, X.; Yang, P.; Zhang, S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiol. Cardiothorac. Imaging 2020, 2, e200067.
  2. Danzi, G.B.; Loffi, M.; Galeazzi, G.; Gherbesi, E. Acute pulmonary embolism and COVID-19 pneumonia: A random association? Eur. Hear. J. 2020, 41, 1858.
  3. Cui, S.; Chen, S.; Li, X.; Liu, S.; Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020, 18, 1421–1424.
  4. Klok, F.A.; Kruip, M.J.; Van der Meer, N.J.; Arbous, M.S.; Gommers, D.A.; Kant, K.M.; Kaptein, F.H.; van Paassen, J.; Stals, M.A.; Huisman, M.V.; et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020, 191, 145–1457.
  5. Vedantham, S.; Goldhaber, S.Z.; Julian, J.A.; Kahn, S.R.; Jaff, M.R.; Cohen, D.J.; Magnuson, E.; Razavi, M.K.; Comerota, A.J.; Gornik, H.L.; et al. ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein throm-bosis. N. Engl. J. Med. 2017, 377, 2240–2252.
  6. Konstantinides, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.J.; Harjola, V.P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D.; et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 2020, 41, 543–603.
  7. Chodakowski, J.D.; Courtney, D.M. Pulmonary embolism critical care update: Prognosis, treatment, and research gaps. Curr. Opin. Crit. Care 2018, 24, 540–546.
  8. Barnes, G.D.; Kabrhel, C.; Courtney, D.M.; Naydenov, S.; Wood, T.; Rosovsky, R.; Rosenfield, K.; Giri, J.; National PERT Consortium Research Committee. Diversity in the pulmonary embolism response team model: An organizational survey of the National PERT Consortium Members. Chest 2016, 150, 1414–1417.
  9. Rosovsky, R.; Zhao, K.; Sista, A.; Rivera-Lebron, B.; Kabrhel, C. Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. Res. Pr. Thromb. Haemost. 2019, 3, 315–330.
  10. Bikdeli, B.; Chatterjee, S.; Desai, N.R.; Kirtane, A.J.; Desai, M.M.; Bracken, M.B.; Spencer, F.A.; Monreal, M.; Goldhaber, S.Z.; Krumholz, H.M. Inferior vena cava filters to prevent pulmonary embolism: Systematic review and meta-analysis. J. Am. Coll. Cardiol. 2017, 70, 1587–1597.
  11. Kearon, C.; Akl, E.A.; Ornelas, J.; Blaivas, A.; Jimenez, D.; Bounameaux, H.; Huisman, M.; King, C.S.; Morris, T.A.; Sood, N.; et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016, 149, 315–352.
  12. Piazza, G. Advanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar. J. Am. Coll. Cardiol. 2020, 76, 2117–2127.
  13. Giri, J.; Sista, A.K.; Weinberg, I.; Kearon, C.; Kumbhani, D.J.; Desai, N.D.; Piazza, G.; Gladwin, M.T.; Chatterjee, S.; Kobayashi, T.; et al. Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation 2019, 140, e774–e801.
  14. Jimenez, D.; Bikdeli, B.; Marshall, P.S.; Tapson, V. Aggressive Treatment of Intermediate-Risk Patients with Acute Symptomatic Pulmonary Embolism. Clin. Chest Med. 2018, 39, 569–581.
  15. Pellegrini, J.A.S.; Rech, T.H.; Schwarz, P.; de Oliveira, A.C.T.; Vieceli, T.; Moraes, R.B.; Sekine, L.; Viana, M.V. Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: A prospective cohort study. J. Thromb. Thrombolysis 2021, 1–11.
  16. Moll, M.; Zon, R.L.; Sylvester, K.W.; Chen, E.C.; Cheng, V.; Connell, N.T.; Fredenburgh, L.E.; Baron, R.M.; Cho, M.H.; Woolley, A.E.; et al. VTE in ICU Patients With COVID-19. Chest 2020, 158, 2130–2135.
  17. Di Minno, A.; Ambrosino, P.; Calcaterra, I.; Di Minno, M.N.D. COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin. Thromb. Hemost. 2020, 46, 763–771.
  18. Mansfield, A.; Tafur, A.; Vulih, D.; Smith, G.; Harris, P.; Ivy, S. Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials. Thromb. Res. 2015, 136, 1169–1173.
  19. Smith, B.S.; Yogaratnam, D.; Levasseur-Franklin, K.E.; Forni, A.; Fong, J. Introduction to Drug Pharmacokinetics in the Critically III Patient. Chest 2012, 141, 1327–1336.
  20. Aryal, M.R.; Gosain, R.; Donato, A.; Pathak, R.; Bhatt, V.R.; Katel, A.; Kouides, P. Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thrombo-prophylaxis, Screening, and Treatment. Curr. Cardiol. Rep. 2020, 22, 52.
  21. Sklar, M.C.; Sy, E.; Lequier, L.; Fan, E.; Kanji, H.D. Anticoagulation practices during venovenous extracorporeal membrane oxy-genation for respiratory failure. A systematic review. Ann. Am. Thorac. Soc. 2016, 13, 2242–2250.
  22. Yang, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062.
  23. Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020, 8, 475–481.
  24. Extracorporeal Life Support Organization. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. v1.4. 2017. Available online: (accessed on 1 April 2020).
  25. Dobesh, P.P.; Trujillo, T.C. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2020, 40, 1130–1151.
  26. Schunemann, H.J.; Cushman, M.; Burnett, A.E.; Kahn, S.R.; Beyer-Westendorf, J.; Spencer, F.A.; Rezende, S.M.; Zakai, N.A.; Bauer, K.A.; Dentali, F.; et al. American Society of Hematology 2018 guidelines for management of ve-nous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018, 2, 3198–3225.
  27. Lopes, R.D.; de Barros ESilva, P.G.M.; Furtado, R.H.M.; Macedo, A.V.S.; Ramacciotti, E.; Damini, L.P.; Bronhara, B.; Cavalcanti, A.B.; Rosa, R.G.; Azevedo, L.C.P.; et al. Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) Admitted to Hospital: Rationale and Design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV Trial. Am. Heart J. 2021.
  28. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 92: Venous Thromboembolism: Reducing the Risk. Available online: (accessed on 30 March 2020).
  29. Lenchus, J.D.; Biehl, M.; Cabrera, J.; De Moraes, A.G.; Dezfulian, C. In-Hospital Management and Follow-Up Treatment of Venous Thromboembolism: Focus on New and Emerging Treatments. J. Intensiv. Care Med. 2017, 32, 299–311.
  30. Encke, A.; Haas, S.; Kopp, I. The Prophylaxis of Venous Thromboembolism. Dtsch. Aerzteblatt Online 2016, 113, 532–538.
  31. Spyropoulos, A.C.; Levy, J.H.; Ageno, W.; Connors, J.M.; Hunt, B.J.; Iba, T.; Levi, M.; Samama, C.M.; Thachil, J.; Giannis, D.; et al. Scientific and Stand-ardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous throm-boembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 2020, 18, 1859–1865.
  32. Albertsen, I.E.; Nielsen, P.B. Searching for High-Risk Venous Thromboembolism Patients Using Risk Scores: Adding to the Heap or Closing a Gap? Thromb. Haemost. 2018, 118, 1686–1687.
  33. Zhou, H.; Hu, Y.; Li, X.; Wang, L.; Wang, M.; Xiao, J.; Yi, Q. Assessment of the Risk of Venous Thromboembolism in Medical Inpatients using the Padua Prediction Score and Caprini Risk Assessment Model. J. Atheroscler. Thromb. 2018, 25, 1091–1104.
  34. Stuck, A.; Spirk, D.; Schaudt, J.; Kucher, N. Risk Assessment Models for Venous Thromboembolism in Acutely Ill Medical Patients: A Systematic Review. Thromb. Haemost. 2017, 5, 769–770.
  35. Liu, X.; Liu, C.; Chen, X.; Wu, W.; Lu, G. Comparison between Caprini and Padua risk assessment models for hospitalized medi-cal patients at risk for venous thromboembolism: A retrospective study. Interact. Cardiovasc. Thorac. Surg. 2016, 23, 538–543.
  36. Moumneh, T.; Riou, J.; Douillet, D.; Henni, S.; Mottier, D.; Tritschler, T.; Le Gal, G.; Roy, P. Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: A cohort study. J. Thromb. Haemost. 2020, 18, 1398–1407.
  37. Mlaver, E.; Lynde, G.C.; Gallion, C.; Sweeney, J.F.; Sharma, J. Development of a Novel Preoperative Venous Thromboembolism Risk Assessment Model. Am. Surg. 2020, 86.
  38. Wang, T.; Chen, R.; Liu, C.; Liang, W.; Guan, W.; Tang, R.; Tang, C.; Zhang, N.; Zhong, N.; Li, S. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020, 7, e362–e363.
  39. Hunt, B.J. Hemostasis at Extremes of Body Weight. Semin. Thromb. Hemost. 2018, 44, 632–639.
  40. World Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection Is Suspected. INTERIM Guidance 28 January 2020. Available online: (accessed on 7 April 2020).
  41. Liew, N.C.; Alemany, G.V.; Angchaisuksiri, P.; Bang, S.M.; Choi, G.; De Silva, D.; Hong, J.M.; Lee, L.; Li, Y.J.; Rajamoney, G.N.; et al. Asian venous thromboembolism guidelines: Updated recommendations for the prevention of venous thromboembolism. Int. Angiol. 2016, 36, 1–20.
  42. Popoola, V.O.; Tavakoli, F.; Lau, B.D.; Lankiewicz, M.; Ross, P.; Kraus, P.; Shaffer, D.; Hobson, D.B.; Aboagye, J.K.; Farrow, N.A.; et al. Exploring the impact of route of administration on medication acceptance in hospi-talized patients: Implications for venous thromboembolism prevention. Thromb. Res. 2017, 160, 109–113.
  43. Bates, S.M.; Rajasekhar, A.; Middeldorp, S.; McLintock, C.; Rodger, M.A.; James, A.H.; Vazquez, S.R.; Greer, I.A.; Riva, J.J.; Bhatt, M.; et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Adv. 2018, 2, 3317–3359.
  44. Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-Top Guideline No. 37a. 2015. Available online: (accessed on 1 April 2020).
  45. Rybstein, M.D.; DeSancho, M.T. Risk factors for and clinical management of venous thromboembolism during pregnancy. Clin. Adv. Hematol. Oncol. 2019, 17, 396–404.
  46. Akel, T.; Qaqa, F.; Abuarqoub, A.; Shamoon, F. Pulmonary embolism: A complication of COVID 19 infection. Thromb. Res. 2020, 193, 79–82.
  47. Cohen, A.T.; Harrington, R.A.; Goldhaber, S.Z.; Hull, R.D.; Wiens, B.L.; Gold, A.; Hernandez, A.F.; Gibson, C.M.; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical pa-tients. N. Engl. J. Med. 2016, 375, 534–544.
  48. Arigondam, A.K.; Hakeem, A.R.; Reddy, M.S.; Rela, M. An Evidence-based Protocol for Minimizing Thromboembolic Events in SARS-CoV-2 Infection. Arch. Med. Res. 2021, 52, 252–260.
  49. Spyropoulos, A.C.; Ageno, W.; Albers, G.W.; Elliott, C.G.; Halperin, J.L.; Hiatt, W.R.; Maynard, G.A.; Steg, P.G.; Weitz, J.I.; Suh, E.; et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical ill-ness. N. Engl. J. Med. 2018, 379, 1118–1127.
  50. Spyropoulos, A.C.; Lipardi, C.; Xu, J.; Peluso, C.; Spiro, T.E.; De Sanctis, Y.; Barnathan, E.S.; Raskob, G.E. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open 2020, 4, e59–e65.
  51. Dentali, F.; Mumoli, N.; Prisco, D.; Fontanella, A.; Di Minno, M.N. Efficacy and safety of extended thromboprophylaxis for medi-cally ill patients. A meta-analysis of randomised controlled trials. Thromb. Haemost. 2017, 117, 606–617.
  52. Schindewolf, M.; Weitz, J.I. Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thromb. Haemost. 2019, 120, 14–26.
  53. Spyropoulos, A.C.; Lipardi, C.; Xu, J.; Lu, W.; Suh, E.; Yuan, Z.; Levitan, B.; Sugarmann, C.; De Sanctis, Y.; Spiro, T.E.; et al. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin. Appl. Thromb. Hemost. 2019, 25.
  54. Chi, G.; Goldhaber, S.Z.; Kittelson, J.M.; Turpie, A.G.G.; Hernandez, A.F.; Hull, R.D.; Gold, A.; Curnutte, J.T.; Cohen, A.T.; Harrington, R.A.; et al. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: A bivariate analysis. J. Thromb. Haemost. 2017, 15, 1913–1922.
  55. Zhang, A.; Leng, Y.; Zhang, Y.; Wu, K.; Ji, Y.; Lei, S.; Xia, Z. Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19. Int. J. Infect. Dis. 2020, 100, 441–448.
  56. Iba, T.; Levy, J.H.; Levi, M.; Thachil, J. Coagulopathy in COVID-19. J. Thromb. Haemost. 2020, 18, 2103–2109.
  57. Gando, S.; Shiraishi, A.; Yamakawa, K.; Ogura, H.; Saitoh, D.; Fujishima, S.; Mayumi, T.; Kushimoto, S.; Abe, T.; Shiino, Y.; et al. Japanese Association for Acute Medicine (JAAM) Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis and Trauma (FORECAST) Study Group. Role of disseminated intravascular coagulation in severe sepsis. Thromb Res. 2019, 178, 182–188.
  58. Jackson Chornenki, N.L.; Dwivedi, D.J.; Kwong, A.C.; Zamir, N.; Fox-Robichaud, A.E.; Liaw, P.C.; Canadian Critical Care Translational Biology Group. Canadian Critical Care Translational Biology Group. Identification of hemostatic markers that define the pre-DIC state: A multi-center observational study. J. Thromb. Haemost. 2020, 18, 2524–2531.
  59. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coro-navirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020.
  60. Wada, H.; Thachil, J.; Di Nisio, M.; Mathew, P.; Kurosawa, S.; Gando, S.; Kim, H.K.; Nielsen, J.D.; Dempfle, C.E.; Levi, M.; et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommenda-tions from 3 guidelines. J. Thromb. Haemost. 2013.
  61. Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020, 395, 1417–1418.
  62. Perico, L.; Benigni, A.; Casiraghi, F.; Ng, L.F.P.; Renia, L.; Remuzzi, G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol. 2021, 17, 46–64.
  63. Monteil, V.; Kwon, H.; Prado, P.; Hagelkrüys, A.; Wimmer, R.A.; Stahl, M.; Leopoldi, A.; Garreta, E.; Del Pozo, C.H.; Prosper, F.; et al. Inhibition of SARS-CoV-2 Infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020, 181, 905–913.e7.
  64. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020, 395, 1033–1034.
  65. Jackson, B.S.; Pretorius, E. Pathological Clotting and Deep Vein Thrombosis in Patients with HIV. Semin. Thromb. Hemost. 2019, 45, 132–140.
  66. Ramacciotti, E.; Agati, L.B.; Aguiar, V.C.R.; Wolosker, N.; Guerra, J.C.; De Almeida, R.P.; Alves, J.C.; Lopes, R.D.; Wakefield, T.W.; Comerota, A.J.; et al. Zika and Chikungunya Virus and Risk for Venous Thromboembolism. Clin. Appl. Thromb. 2019, 25.
  67. Smither, S.J.; O’Brien, L.M.; Eastaugh, L.; Woolley, T.; Lever, S.; Fletcher, T.; Parmar, K.; Hunt, B.J.; Watts, S.; Kirkman, E. Haemostatic Changes in Five Patients Infected with Ebola Virus. Viruses 2019, 11, 647.
  68. Karakike, E.; Giamarellos-Bourboulis, E.J. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front. Immunol. 2019, 10, 55.
  69. McGonagle, D.; Sharif, K.; O’Regan, A.; Bridgewood, C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020, 19, 102537.
  70. Webb, B.J.; Peltan, I.D.; Jensen, P.; Hoda, D.; Hunter, B.; Silver, A.; Starr, N.; Buckel, W.; Grisel, N.; Hummel, E.; et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: A co-hort study. Lancet Rheumatol. 2020, 2, e754–e763.
  71. Peng, Z.; Shu, B.; Zhang, Y.; Wang, M. Endothelial Response to Pathophysiological Stress. Arter. Thromb. Vasc. Biol. 2019, 39, e233–e243.
  72. Gimbrone, M.A., Jr.; Garcia-Cardena, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016, 118, 620–636.
  73. Milenkovic, J.; Milojkovic, M.; Stoimenov, T.J.; Djindjic, B.; Miljkovic, E. Mechanisms of plasminogen activator inhibitor 1 action in stromal remodeling and related diseases. Biomed. Pap. Med. Fac. Palacky Univ. Olomouc 2017, 161, 339–347.
  74. Poels, K.; van Leent, M.M.; Reiche, M.E.; Kusters, P.J.; Huveneers, S.; de Winther, M.P.; Mulder, W.J.; Lutgens, E.; Seijkens, T.T. Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque In-flammation and Progression in Hyperlipidemic Mice. Cells 2020, 9, 1987.
  75. Matsumoto, T.; Sasaki, N.; Yamashita, T.; Emoto, T.; Kasahara, K.; Mizoguchi, T.; Hayashi, T.; Yodoi, K.; Kitano, N.; Saito, T.; et al. Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Ath-erosclerosis in Mice. Arter. Thromb. Vasc. Biol. 2016, 36, 1141–1151.
  76. Foks, A.; Kuiper, J. Immune checkpoint proteins: Exploring their therapeutic potential to regulate atherosclerosis. Br. J. Pharmacol. 2017, 174, 3940–3955.
  77. Zuo, Y.; Warnock, M.; Harbaugh, A.; Yalavarthi, S.; Gockman, K.; Zuo, M.; Madison, J.A.; Knight, J.S.; Kanthi, Y.; Lawrence, D.A. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci. Rep. 2021, 11, 1–9.
  78. Engin, A. Endothelial Dysfunction in Obesity. Adv. Exp. Med. Biol. 2017, 960, 345–379.
  79. Yang, J.; Hu, J.; Zhu, C. Obesity aggravates COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2020, 93, 257–261.
  80. Hariyanto, T.I.; Kurniawan, A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1463–1465.
  81. Picard, F.; Adjedj, J.; Varenne, O. Diabetes Mellitus, a prothrombotic disease. Ann. Cardiol. D’angeiologie 2017, 66, 385–392.
  82. Bryk, A.H.; Satała, D.; Natorska, J.; Rąpała-Kozik, M.; Undas, A. Interaction of glycated and acetylated human α2-antiplasmin with fibrin clots. Blood Coagul. Fibrinolysis 2020, 31, 393–396.
  83. Yazıcı, D.; Sezer, H. Insulin Resistance, Obesity and Lipotoxicity. Adv. Exp. Med. Biol. 2017, 960, 277–304.
  84. Cooper, I.D.; Crofts, C.A.P.; DiNicolantonio, J.J.; Malhotra, A.; Elliott, B.; Kyriakidou, Y.; Brookler, K.H. Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: Rationale for clinical management. Open Hear. 2020, 7, e001356.
  85. Hansen, M.E.; Tippetts, T.S.; Anderson, M.C.; Holub, Z.E.; Moulton, E.R.; Swensen, A.C.; Prince, J.T.; Bikman, B.T. Insulin Increases Ceramide Synthesis in Skeletal Muscle. J. Diabetes Res. 2014, 2014, 1–9.
  86. Dias, I.H.; Ferreira, R.; Gruber, F.; Vitorino, R.; Rivas-Urbina, A.; Sanchez-Quesada, J.L.; Silva, J.V.; Fardilha, M.; de Freitas, V.; Reis, A. Sulfate-based lipids: Analysis of healthy human fluids and cell extracts. Chem. Phys. Lipids 2019, 221, 53–64.
  87. Janssen, R.; Visser, M.P.J.; Dofferhoff, A.S.M.; Vermeer, C.; Janssens, W.; Walk, J. Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019. Br. J. Nutr. 2020, 1–8.
  88. Iba, T.; Levy, J.H. Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. Anesthesiology 2020, 132, 1238–1245.
  89. Hayden, M.R. Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019. J. Int. Med. Res. 2020, 48.
  90. Hotta, Y.; Kataoka, T.; Kimura, K. Testosterone Deficiency and Endothelial Dysfunction: Nitric Oxide, Asymmetric Dimethylarginine, and Endothelial Progenitor Cells. Sex. Med. Rev. 2019, 7, 661–668.
  91. Giagulli, V.A.; Guastamacchia, E.; Magrone, T.; Jirillo, E.; Lisco, G.; De Pergola, G.; Triggiani, V. Worse progression of COVID-19 in men: Is testosterone a key factor? Andrology 2021, 9, 53–64.
  92. Zhang, Y.; Xiao, M.; Zhang, S.; Xia, P.; Cao, W.; Jiang, W.; Chen, H.; Ding, X.; Zhao, H.; Zhang, H.; et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N. Engl. J. Med. 2020, 382, e38.
  93. Greinacher, A.; Thiele, T.; Warkentin, T.E.; Weisser, K.; Kyrle, P.A.; Eichinger, S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback